India's largest biotechnology firm Biocon Ltd. said that the Drug Controller General of India has granted approval to market its BIOMAb EGFR treatment for head and neck cancer in India.
{{^htLoading}} {{/htLoading}}
The initial human clinical trials for its oral insulin molecule, IN105, have also begun and will be completed by the third quarter of fiscal 2006/07, Biocon said in a statement.
Follow India news real-time updates and the latest news covered on Hindustan Times, featuring today's critical updates on Sonam Wangchuk LIVE and more across India.
Follow India news real-time updates and the latest news covered on Hindustan Times, featuring today's critical updates on Sonam Wangchuk LIVE and more across India.
Advertisement
{{/htLoading}}{{#usCountry}}